Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michael Greico

Physician Assistant, Medical Millville, NJ Physician Assistant

NPI 1689102055 CMS profile 10567030

1700 N 10Th St, Millville, NJ 08332

Open in the dashboard

General payments

$8,485

450 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Greico of Millville, NJ is reported in the CMS Open Payments database as having received $8,485 across 450 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $194 12
2024 General $1,776 86
2023 General $2,138 108
2022 General $2,372 132
2021 General $2,004 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Greico
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Michael Greico were reported at $194. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Michael Greico Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,004 $156 $41–$563 $132
2022 $2,372 $185 $55–$649 $149
2023 $2,138 $199 $58–$717 $160
2024 $1,776 $206 $62–$740 $164
2025 $194 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,615 61 payments
  2. AbbVie, Inc. $1,022 59 payments
  3. Novo Nordisk Inc $918 63 payments
  4. Lilly USA, LLC $619 28 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $540 26 payments
  6. GlaxoSmithKline, LLC. $329 23 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $286 26 payments
  8. Otsuka America Pharmaceutical, Inc. $277 10 payments
  9. Astellas Pharma US Inc $256 17 payments
  10. Idorsia Pharmaceuticals US Inc $233 16 payments
  11. Other $2,389 121 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,478 449 payments
  2. Education $7 1 payment
Products named General payments · program years 2021–2025
  1. FARXIGA $791 26 payments
  2. BREZTRI $684 24 payments
  3. UBRELVY $654 25 payments
  4. RYBELSUS $629 37 payments
  5. Ozempic $542 38 payments
  6. JARDIANCE $429 19 payments
  7. MOUNJARO $425 14 payments
  8. QULIPTA $309 13 payments
  9. XIFAXAN $286 26 payments
  10. TRELEGY ELLIPTA $284 20 payments
  11. Other $5,305 320 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

450 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record